A Trial of SHR-A2102 With Adebrelimab With or Without Other Anti-tumor Therapies in Recurrent/MetastaticHead and Neck Squamous Cell Carcinoma Cancer

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Chongqing University Cancer Hospital, Chongqing, Chongqing Municipality, China
Contact: Principal Investigator (Ying Wang)
West China Hospital of Sichuan University, Chengdu, Sichuan, China
Contact: Principal Investigator (Lei Liu)

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer

Head and Neck Squamous Cell Carcinoma · Recurrent Head and Neck Squamous Cell Carcinoma · Metastatic Head-and-neck Squamous-cell Carcinoma

Abroad (travel likely)RecruitingPHASE2

Winston-Salem, United States

A Study of Pembrolizumab in Combination With Chemotherapy for Head and Neck Cancer

Head and Neck Cancer · Head and Neck Squamous Cell Carcinoma · Head and Neck Neoplasms

Abroad (travel likely)RecruitingPHASE2

Chicago, United States

Pulsed Dose Chemotherapy Plus Pembrolizumab in Recurrent/Metastatic HNSCC

Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)

Abroad (travel likely)RecruitingPHASE2

Pittsburgh, United States

A Study of Nimotuzumab Plus Adebrelimab With Chemotherapy in Cisplatin-Ineligible Patients With Head And Neck Squamous Cell Carcinoma

Head and Neck Squamous Cell Carcinoma

Abroad (travel likely)RecruitingPHASE1, PHASE2

Shanghai, China